Stockreport

How The Royalty Pharma (RPRX) Story Is Shifting With New Deals And Updated Expectations [Yahoo! Finance]

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF Royalty Pharma's updated fair value price target now sits at US$51.56, compared with the previous US$51.00 level. Analysts linking this shift to current Street commenta [Read more]